We scan new podcasts and send you the top 5 insights daily.
Dr. Bazanova says the LUMINOSITY trial's intermediate group, defined as 3+ staining in 25% to 50% of cells, had a 23% response rate and about seven-month median duration. That group is outside the current FDA indication, although the ongoing TELIMET trial now enrolls these patients.
The accelerated FDA approval of Taliso-V for CMET overexpression creates a new treatment category, distinct from previously targeted MET exon 14 skipping mutations. This validates IHC-based protein overexpression as an independent, actionable biomarker, expanding targeted therapy options for a new patient population that previously had none.
The SAVANNAH study showed that targeting MET amplification after TKI failure is only effective with stringent diagnostic criteria (e.g., IHC 3+ in >90% of cells). Lower cutoffs lead to poor outcomes, highlighting the need for precise biomarker testing to select patients for this therapy.
Clinical trials for MET-targeted therapies in NSCLC use varying definitions for MET amplification, including different Gene Copy Number (GCN) or MET-CEP7 ratio cutoffs. This inconsistency makes it challenging to compare drug efficacy and apply trial data directly to clinical practice.
Despite newer MET TKIs like capmatinib and tipotinib being available, the older drug crizotinib remains a valuable option for NSCLC patients with MET alterations. It is often better tolerated, making it a practical choice for patients who cannot handle the side effects of newer agents.
Dr. Bazanova says acquired MET overexpression can appear after EGFR-targeted therapy, so her standard practice is to repeat biopsy and order both NGS and IHC at progression. That acquired finding can open use of a MET-directed therapy in patients whose earlier biopsy lacked the target.
Standard Next-Generation Sequencing (NGS) reports often just state "MET amplification" without a specific copy number. To make informed treatment decisions with MET inhibitors, clinicians must proactively contact the testing company's molecular pathology department to obtain this crucial, unlisted data point.
Dr. Bazanova says she orders both in practice because IHC measures surface protein while NGS reads gene-level changes, and each can trigger different therapy. A high IHC result without a MET mutation or amplification is not discordant; it tells a separate part of the tumor's biology.
Contrary to the standard 'TKI-first' approach for driver mutations, a study in MET exon 14 skipping NSCLC suggests a different strategy. Patients with high PD-L1 expression appeared to have better outcomes with first-line chemoimmunotherapy, reserving the targeted therapy for later. This challenges the conventional wisdom of prioritizing the driver mutation over immunotherapy biomarkers in this specific subgroup.
In the Luminosity study of Taliso-V for MET-overexpressed NSCLC, patients with high C-MET expression had better response rates than those with intermediate expression. However, this did not translate into a significant improvement in median Progression-Free Survival (PFS) or Overall Survival (OS).
Dr. Patel says telisotuzumab has better efficacy and less toxicity than docetaxel in MET-high second-line NSCLC. He says giving a similar cytotoxic first can blunt the ADC, so he prefers chemoimmunotherapy first and then the MET-directed ADC at progression rather than docetaxel first for those patients.